US healthcare stocks finished the week on a high note Friday, with biotech names leading the charge after upbeat comments about artificial intelligence from Doximity, a digital platform for clinicians, helped lift sentiment across the sector.
By Friday afternoon, the NYSE Healthcare Index was up 0.4%, the Health Care Select Sector SPDR Fund had gained 0.6%, and the iShares Biotechnology ETF was up 2%. The pattern suggests investors were rotating toward the riskier, innovation-heavy parts of healthcare, rather than the defensive, steady-growth names that usually dominate the sector.
Doximity's AI moment
The day's flashpoint was Doximity, which runs a social network and communication platform used by doctors and other healthcare professionals. The company reported higher fiscal first-quarter revenue and beat expectations on sales, though its adjusted earnings fell short of Wall Street's forecasts.
But the real catalyst came from the company's chief executive, Jeffrey Tangney, who said on the post-earnings call that Doximity's new AI-powered search tool is generating revenue that is 10 times what it costs to run. That kind of return on investment is rare in the world of AI, where many companies are spending heavily on computing power and data with uncertain payoffs.
Investors reacted enthusiastically, sending Doximity's shares up 36% on the day. The surge also helped lift other healthcare technology and biotech stocks, as traders took the news as a sign that AI can deliver real, measurable value in healthcare.
Doximity's AI tool is designed to help clinicians quickly find relevant medical information, such as drug interactions or treatment guidelines. The company has been integrating AI into its platform for a while, and the CEO's comments suggest that the technology is not just a cost center but a genuine revenue driver.
Why biotech led the gains
Biotech stocks are often seen as the most speculative part of the healthcare sector. They tend to be smaller companies with high growth potential but also high risk, as their fortunes depend on clinical trial results, regulatory approvals, and the ability to bring new drugs to market.
When investors feel optimistic about the economy or a particular theme like AI, they often shift money into these riskier areas. Friday's move was a classic example of that rotation: instead of hiding in large-cap pharmaceutical companies or healthcare insurers, which are considered safer bets, investors chased the potential upside in biotech.
The iShares Biotechnology ETF's 2% gain outpaced the broader healthcare indexes, a sign that the AI enthusiasm was particularly strong among the more innovation-focused names.
What it means for investors
For everyday investors, Friday's move is a reminder that healthcare is not a monolithic sector. It spans everything from giant drugmakers and insurers to small biotech startups and healthcare technology firms. Each segment can react very differently to the same news.
The Doximity surge shows that AI is becoming a key driver of stock moves in healthcare, just as it has in technology. Companies that can demonstrate that their AI investments are paying off—by boosting revenue or cutting costs—are likely to be rewarded by investors. Those that can't may see their stocks lag.
It's also worth noting that the broader market backdrop was supportive. A weak US jobs report earlier in the week had cooled expectations for further interest rate hikes, which tends to benefit growth-oriented stocks like biotech. Lower rates make future profits more valuable and reduce the cost of borrowing for cash-hungry startups.
However, investors should be cautious about chasing single-day moves. Doximity's 36% jump is a big move, but it came after the company's earnings report, and such spikes can be volatile. The company's adjusted earnings miss is a reminder that even companies with exciting AI stories can have mixed financial results.
For those looking at the healthcare sector, it's important to understand the difference between the various sub-industries. Biotech ETFs, for example, offer exposure to the riskier end of the spectrum, while healthcare select sector funds are more diversified and include stable, dividend-paying companies.
As always, diversification is key. A portfolio that includes a mix of healthcare subsectors—along with other industries—can help manage risk while still capturing growth opportunities.
The AI theme in healthcare is likely to continue generating headlines. Companies are using AI for everything from drug discovery to patient care, and investors are eager to see which ones can turn that into profits. Friday's action suggests that the market is paying close attention.
